Cellectar Biosciences, Inc. — Q1 2024 Form 10-Q
Business context and reporting period
For the quarter ended March 31, 2024, Cellectar was a clinical-stage biopharmaceutical company developing cancer therapies using its phospholipid drug conjugate platform. Its lead candidate, iopofosine I 131, was being evaluated in several cancer indications. The company reported no product revenue; the filing presents operating expenses and losses.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | No product revenue reported | — |
| Research and development expense | $7.38 million | $6.65 million; up 11% |
| General and administrative expense | $4.62 million | $2.05 million; up 125% |
| Total operating expenses | $12.00 million | $8.71 million |
| Net loss | $21.58 million | $8.58 million |
| Basic and diluted loss per share | $0.74 | $0.76 |
| Cash used in operations | $13.36 million | $7.18 million |
Q1 net loss included a $9.9 million noncash loss from warrant revaluation; interest income was $0.32 million. The company had $40.03 million in cash and cash equivalents at March 31, versus $9.56 million at December 31, 2023. Financing activities provided $43.85 million, primarily from warrant exercises; investing activities used $0.02 million. Current assets were $41.37 million and current liabilities $16.27 million. Total liabilities were $16.74 million, including $8.8 million of warrant liability and approximately $0.55 million of lease liabilities. The filing reports no conventional borrowings.
Material changes and financing
- R&D expense rose mainly because manufacturing and related costs increased by $1.40 million, associated with supply-chain and production sourcing work; lower general R&D costs partly offset the increase.
- G&A expense increased by $2.57 million, which management attributed primarily to building infrastructure for potential commercialization, including marketing and personnel costs.
- Following January topline data from the CLOVER-WaM trial, holders exercised Tranche A warrants, providing $42.8 million in net proceeds. The company also received approximately $1.1 million from other common-warrant exercises. These transactions materially increased cash and common shares outstanding.
- During the quarter, 9.89 million common shares were issued on conversion of Series E-3 preferred stock and 0.90 million on conversion of Series E-2 preferred stock. At March 31, 33.16 million common shares were outstanding; 35.85 million were outstanding May 8.
Outlook, clinical developments, and risks
- Management said March 31 cash was sufficient for basic budgeted operations into Q4 2024. The company expects continuing operating losses and said executing its operating plan beyond that point depends on obtaining additional capital through securities, a strategic transaction, or another source. It is actively pursuing financing, but gives no assurance of success.
- The filing states that these funding uncertainties raise substantial doubt about the company’s ability to continue as a going concern within one year of issuance of the financial statements.
- In CLOVER-WaM, the company reported a 61% major response rate among the reported efficacy population, exceeding the agreed 20% statistical hurdle; overall response was 75.6%, and 100% had disease control. Median duration of response was not reached, and 76% remained progression-free at median follow-up of eight months. These are company-reported topline results from a single-arm trial, not FDA approval.
- Other iopofosine studies were ongoing, including Phase 2b studies in multiple myeloma and CNS lymphoma and a pediatric Phase 1b study in high-grade glioma. Additional PDC programs remained preclinical. Clinical development, regulatory review, manufacturing and funding remain uncertain; the filing also notes adverse events and fatalities have occurred in patients after iopofosine treatment across studies.
- The remaining Tranche B warrants were liability-classified and valued at $8.8 million at quarter-end. Warrants, convertible preferred shares and options represent potential dilution; the filing lists 12.53 million common-stock warrant shares and 6.68 million common shares issuable upon preferred conversion at March 31.
- Management concluded disclosure controls and procedures were ineffective. Material weaknesses involved Level 3 fair-value and technical accounting controls, limited finance staffing and segregation of duties, user access controls, and stock-based compensation accounting. Remediation was underway. The company also cited continued Nasdaq listing compliance as a risk.
Key facts for investors to verify
- Whether subsequent financing, partnering, or other capital activity extends the stated runway beyond Q4 2024 and addresses the going-concern uncertainty.
- Full CLOVER-WaM results, including the final analysis population, response durability, safety follow-up, and regulatory pathway; distinguish topline company-reported data from FDA conclusions.
- Quarterly cash burn and the timing and cost of clinical, manufacturing, and commercialization-readiness activities.
- Warrant and preferred-stock terms, potential share issuance and dilution, and changes in the fair value of liability-classified warrants.
- Progress in remediating internal-control weaknesses and maintaining Nasdaq listing compliance.